...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain
【24h】

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

机译：MeNZB：一种针对新西兰脑膜炎奈瑟氏球菌血清B型流行病株的安全且高度免疫原性的量身定制疫苗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clinical studies have been conducted in New Zealand evaluating the safety and immunogenicity of an outer membrane vesicle (OMV) vaccine, MeNZB, developed to control epidemic disease caused by group B meningococci, subtype P1.7b,4. MeNZB, administered in a three-dose regimen, was well tolerated and induced a seroresponse, defined as a four-fold rise (> or =titre 8) in serum bactericidal antibodies against the vaccine strain 4-6 weeks after the third vaccination, in 96% (95% confidence interval (CI): 79-100%) of adults, 76% (95% CI: 72-80%) of children, 75% (95% CI: 69-80%) of toddlers and 74% (95% CI: 67-80%) of infants receiving MeNZB. In conclusion, these findings suggest that MeNZB is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain.
机译：在新西兰进行了临床研究，评估了为控制由B组脑膜炎球菌P1.7b，4亚型引起的流行病而开发的外膜囊泡（OMV）疫苗MeNZB的安全性和免疫原性。在三剂疫苗接种后，MeNZB具有良好的耐受性，并诱导了血清反应，即血清抗疫苗疫苗血清杀菌抗体的4倍升高（≥8）。 96％（95％置信区间（CI）：79-100％）的成年人，76％（95％CI：72-80％）的儿童，75％（95％CI：69-80％）的幼儿和74 ％（95％CI：67-80％）接受MeNZB的婴儿。总之，这些发现表明，MeNZB是安全的，并且可能针对由该流行株引起的系统性B组脑膜炎球菌疾病提供保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号